Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Protagonist Therapeutics Inc PTGX

Healthcare Biotechnology
Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its... see more

Recent & Breaking News (NDAQ:PTGX)

TOP RANKED ROSEN LAW FIRM Encourages Protagonist Therapeutics, Inc. Investors with Losses to Inquire About Securities Class Action Investigation - PTGX

PR Newswire April 24, 2022

Ongoing Investigation Alert: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile April 22, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Protagonist Therapeutics, Inc. - PTGX

Newsfile April 21, 2022

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. With Losses of $100,000 to Contact the Firm

Business Wire April 20, 2022

EQUITY ALERT: Rosen Law Firm Encourages Protagonist Therapeutics, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation - PTGX

Business Wire April 20, 2022

Protagonist Therapeutics Reports Granting of Inducement Awards

PR Newswire April 19, 2022

Protagonist Therapeutics Announces Appointment of Asif Ali as Executive Vice President and Chief Financial Officer

PR Newswire March 28, 2022

Protagonist Therapeutics Earns $25 Million Milestone Payment from Janssen Biotech for Dosing of Third Patient in Phase 2b Clinical Trial of PN-235 in Moderate-to-Severe Plaque Psoriasis

PR Newswire March 16, 2022

Protagonist Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update

PR Newswire February 28, 2022

Protagonist Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

PR Newswire February 10, 2022

Protagonist Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

PR Newswire January 4, 2022

Protagonist Therapeutics Presents Updated Phase 2 Rusfertide Data in Polycythemia Vera (PV) at ASH 2021 Annual Meeting

PR Newswire December 12, 2021

Protagonist Therapeutics to Present at the JMP Securities Hematology and Oncology Summit

PR Newswire December 3, 2021

Protagonist Therapeutics Announces the Selection of Oral Peptide PN-235 into Phase 2 Clinical Development Program for Multiple Indications

PR Newswire December 2, 2021

Protagonist Therapeutics Announces Positive Phase 2a Data Supporting the Potential Use of Rusfertide as a First-in-Class Therapy in Hereditary Hemochromatosis

PR Newswire November 15, 2021

Protagonist Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences

PR Newswire November 11, 2021

Protagonist Therapeutics Announces Updated Data from Phase 2 Study of Rusfertide in Polycythemia Vera Selected for Oral Presentations at the ASH 2021 Annual Meeting

PR Newswire November 4, 2021

Protagonist Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

PR Newswire November 3, 2021

Protagonist Therapeutics Earns $7.5 Million Milestone Payment from IL-23 Receptor Collaboration with Janssen

PR Newswire October 26, 2021

Protagonist Therapeutics to Present at the Jefferies Next Generation IBD Therapeutics Summit

PR Newswire October 12, 2021